Assessing SGLT-2 Inhibitors in Patients with T2D, Cardiovascular Complications | AHA 2024
Three research posters presented at the American Heart Association’s 2024 Scientific Sessions looked into the use of SGLT-2 inhibitors in patients with type 2 diabetes and cardiovascular complications.
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are approved for use in patients with type 2 diabetes (T2D) alongside diet and exercise to lower blood sugar. The class of medications, which includes canagliflozin, dapagliflozin and empagliflozin, cause the kidneys to remove sugar from the body through urine. In previous research, SGLT-2 inhibitors have shown to reduce the risk of cardiovascular complications in patients with T2D.
Three research posters presented at the American Heart Association’s 2024 Scientific Sessions, held November 16 to 18 in Chicago, Illinois looked deeper into the use of SGLT-2 inhibitors in patients with T2D and cardiovascular complications, examining SGLT-2 inhibitors following heart failure hospitalization, their impact on cardiorenal outcomes and in reducing the risk of all-cause mortality in patients with T2D and coronary artery disease.
READ MORE: Diabetes Resource Center
Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips, straight to your inbox.
